Compare Carparts.Com Inc (PRTS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Carparts.Com Inc trades at $8.63 (market cap $66.42M), while Vertex Pharmaceuticals Incorporated trades at $511.7 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 1920.4× Carparts.Com Inc's market cap, and Carparts.Com Inc is more actively traded (40,287 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PRTS | VRTX | |
|---|---|---|
Market Cap | $66.42M | $127.55B |
Volume | 40,287 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $557.96 |
52-Week Low | $3.88 | $407.37 |
Typical Hold Time | 45 Days | 120 Days |
Enterprise Value | $79.39M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRTS trades at $8.51, down 2.13% today, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats but remains unprofitable with negative margins. Revenue has declined from $676M in 2023 to $548M in 2025, though net losses improved in recent quarters. Analyst sentiment is positive with 60% buy ratings.
The outlook balances technical strength against fundamental challenges. While the stock shows bullish momentum and analyst support, persistent losses and declining revenue pose significant risks. Investment opportunity exists if the company can stabilize revenue and achieve profitability, but current financial performance warrants caution despite positive earnings surprises.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
